CARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6716 USD | -5.02% |
|
-8.24% | -9.61% |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Denise, and I will ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.6716
USD
Average target price
5.12
USD
Spread / Average Target
+662.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.61% | 38.66M | |
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| -21.94% | 28.08B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Transcript : Cara Therapeutics, Inc., Q2 2022 Earnings Call, Aug 08, 2022
